使用B细胞耗竭药物的患者中严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染的长期及成功治疗：一种定制化方法
Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach.
作者信息
D'Abramo Alessandra, Vita Serena, Maffongelli Gaetano, Mariano Andrea, Agrati Chiara, Castilletti Concetta, Goletti Delia, Ippolito Giuseppe, Nicastri Emanuele
机构信息
National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS, via Portuense 292, 00149, Rome, Italy.
National Institute for Infectious Diseases 'Lazzaro Spallanzani' IRCCS, via Portuense 292, 00149, Rome, Italy.
出版信息
Int J Infect Dis. 2021 Jun;107:247-250. doi: 10.1016/j.ijid.2021.04.068. Epub 2021 Apr 24.
Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs the adaptive immune response, causing severe manifestations during COronaVIrus Disease-2019 (COVID-19). The cases of two patients under anti-CD20 therapy who experienced prolonged and severe COVID-19 successfully treated with mAbs against Severe Acute Respiratory Syndrome-CoV-2 spike proteins are reported.
抗CD20单克隆抗体（mAbs）治疗导致的B细胞长期耗竭会损害适应性免疫反应，在2019冠状病毒病（COVID-19）期间引发严重症状。本文报告了两例接受抗CD20治疗的患者，他们经历了长时间的严重COVID-19，并通过针对严重急性呼吸综合征冠状病毒2刺突蛋白的单克隆抗体成功治愈。
Zotero 插件